- Details
- Zach Klaassen and Geoffrey Johnson discuss the SECuRE trial, a phase 1-2 dose escalation expansion study of a PSMA-targeted radiopharmaceutical for prostate cancer using copper 67. This innovative therapy boasts a unique chelator, enhancing drug delivery and reducing systemic leakage. Early results demonstrate promising efficacy and safety, with notable responses observed in patients, including co...
|
- Details
- Alexandra Sokolova discusses her team's study on genomic alterations influencing the response to lutetium-177 PSMA in metastatic castration-resistant prostate cancer. Their research highlights the need for better biomarkers to predict patient outcomes with lutetium-177 PSMA, as not all patients respond to this treatment. Utilizing data from a collaborative database of over 2000 patients, Dr. Sokol...
|
- Details
- Matthew Smith presents the primary analysis of the CYCLONE 2 trial. This global randomized controlled trial investigated the combination of abemaciclib, a CDK4/6 inhibitor, with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). Despite the promising biological rationale and preclinical evidence suggesting potential benefits, the trial did...
|
- Details
- Yu-Wei Chen discusses his research focusing on androgen receptor (AR) and neuroendocrine signatures in prostate cancer using the Caris database. This study classifies prostate tumors into four molecular subgroups, revealing significant insights into their distinct behaviors and treatment responses. Dr. Chen's findings challenge the conventional histological classifications by demonstrating variati...
|
- Details
- Andrea Miyahira speaks with Ulka Vaishampayan who shares insights into her leadership roles, including chairing the phase I team, co-leading the Translational Clinical Research Program, and serving as chief of Ambulatory Clinical Services. Her journey from lymphoma research to GU oncology was sparked by an early passion for clinical trials and a drive to address gaps in prostate, bladder, and kidn...
|
- Details
- Alicia Morgans speaks with Zach Klaassen about his research focusing on the intersection of mental health and prostate cancer care in the veterans’ population. Dr. Klaassen shares insights from his extensive study aimed at creating the world's largest prostate cancer mental health database. Initial findings reveal that veterans with mental health issues are less frequently diagnosed with prostate...
|
- Details
- Andrea Miyahira talks with Hiba Khan about her presentation on germline genetic associations in prostate cancer. Dr. Khan's study, leveraging data from Invitae, explores genetic testing results linked to medical records to identify gene-specific associations and potential disparities in testing among diverse populations. Key findings reveal that BRCA2 is the most common mutation across all demogra...
|
- Details
- Sima Porten provides an overview of the SunRISe-5 trial, a Phase III study evaluating TAR-200, a novel drug delivery system for patients with recurrent high-risk non-muscle invasive bladder cancer (NMIBC) who have not responded to BCG treatment. Speaking with Dr. Sam Chang of Vanderbilt, Dr. Porten explains that TAR-200 releases gemcitabine directly into the bladder over a sustained period, offeri...
|
- Details
- Zach Klaassen and Stacy Loeb discuss the IMPLEMENT Study, which investigates the underutilization of treatment intensification in metastatic hormone-sensitive prostate cancer. Despite guidelines recommending this approach, it is used in less than a third of cases. Phase one of the study identified barriers like limited knowledge of clinical trials and concerns about using up treatment options earl...
|
- Details
- Michael Schweizer discusses findings on Mevrometostat, an EZH2 inhibitor, combined with enzalutamide in treating metastatic castration-resistant prostate cancer (mCRPC). Dr. Schweizer highlights that EZH2 is a significant driver in neuroendocrine prostate cancer (NEPC) development, making it a crucial target for treatment. The Phase I/II trial shows that Mevrometostat combined with enzalutamide yi...
|
